Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Avelumab (Primary) ; PF 4518600 (Primary) ; Utomilumab (Primary) ; Cisplatin
- Indications Cervical cancer; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2018 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 10 Aug 2017 Planned End Date changed from 1 Sep 2022 to 1 Aug 2022.